SynCon® HIV vaccines
Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. HIV is divided into two distinct types, HIV-1 and HIV-2, which display biological and clinical distinctions. Most HIV research focuses on type 1.
There are six HIV-1 subtypes, or clades: A, B, C, D, E and AE. Inovio has completed preliminary studies focused on HIV vaccine PENNVAX®-B targeting clade B to achieve proof of principle in generating immune responses. We have incorporated the knowledge from this HIV program into the design of our multi-clade PENNVAX®-GP vaccine, which is now our lead preventive and therapeutic vaccine that broadly targets global HIV strains.
|Candidate||Geographic Focus||Target Envelope Clades||Target Antigens||Collaborator|
|Clade B||Gag, pol, env||Prophylactic study: HIV Vaccine Trials
Therapeutic study: U. of Pennsylvania
|PENNVAX®-G||Developing regions of Africa and Asia||Clades A, C, D||Gag, env||USMHRP/NIAID|
|PENNVAX®-GP||Developing regions of Africa and Asia||Clades A, C, B||Gag, env, pol||NIH/NIAID/HVTN|